These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 12750119)
1. Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors. Sinha U; Lin PH; Edwards ST; Wong PW; Zhu B; Scarborough RM; Su T; Jia ZJ; Song Y; Zhang P; Clizbe L; Park G; Reed A; Hollenbach SJ; Malinowski J; Arfsten AE Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1098-104. PubMed ID: 12750119 [TBL] [Abstract][Full Text] [Related]
2. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor. Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410 [TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. Quan ML; Liauw AY; Ellis CD; Pruitt JR; Carini DJ; Bostrom LL; Huang PP; Harrison K; Knabb RM; Thoolen MJ; Wong PC; Wexler RR J Med Chem; 1999 Jul; 42(15):2752-9. PubMed ID: 10425086 [TBL] [Abstract][Full Text] [Related]
5. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Hérault JP; Bernat A; Gaich C; Herbert M Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Hauptmann J; Kaiser B; Nowak G; Stürzebecher J; Markwardt F Thromb Haemost; 1990 Apr; 63(2):220-3. PubMed ID: 2363124 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa. Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248 [TBL] [Abstract][Full Text] [Related]
8. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. Wong PC; Crain EJ; Knabb RM; Meade RP; Quan ML; Watson CA; Wexler RR; Wright MR; Slee AM J Pharmacol Exp Ther; 2000 Oct; 295(1):212-8. PubMed ID: 10991981 [TBL] [Abstract][Full Text] [Related]
9. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit. Bostwick JS; Bentley R; Morgan S; Brown K; Chu V; Ewing WR; Spada AP; Pauls H; Perrone MH; Dunwiddie CT; Leadley RJ Thromb Haemost; 1999 Jan; 81(1):157-60. PubMed ID: 10348709 [TBL] [Abstract][Full Text] [Related]
10. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970 [TBL] [Abstract][Full Text] [Related]
11. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442 [TBL] [Abstract][Full Text] [Related]
12. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405 [TBL] [Abstract][Full Text] [Related]
13. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. Suleymanov OD; Szalony JA; Salyers AK; LaChance RM; Parlow JJ; South MS; Wood RS; Nicholson NS J Pharmacol Exp Ther; 2003 Sep; 306(3):1115-21. PubMed ID: 12829728 [TBL] [Abstract][Full Text] [Related]
15. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087 [TBL] [Abstract][Full Text] [Related]
17. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. Hérault JP; Bernat A; Pflieger AM; Lormeau JC; Herbert JM J Pharmacol Exp Ther; 1997 Oct; 283(1):16-22. PubMed ID: 9336303 [TBL] [Abstract][Full Text] [Related]
18. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats. Hérault JP; Perrin B; Jongbloet C; Pflieger AM; Bernat A; Herbert JM Thromb Haemost; 2000 Oct; 84(4):668-74. PubMed ID: 11057868 [TBL] [Abstract][Full Text] [Related]
19. Co-crystal structure and inhibition of factor Xa by PD0313052 identifies structurally stabilized active site residues of factor Xa and prothrombinase. Gould WR; Cladera E; Harris MS; Zhang E; Narasimhan L; Thorn JM; Leadley RJ Biochemistry; 2005 Jul; 44(26):9280-9. PubMed ID: 15981994 [TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]